StreetAlpha.app
Home › Stocks › KNSA

Kiniksa Pharmaceuticals International, plc (KNSA)

Healthcare
$93.89
▲ +0.38%
LAST CLOSE · NOV 20

Kiniksa Pharmaceuticals develops and sells ARCALYST, a treatment for recurrent pericarditis and other inflammatory conditions. It last closed at $93.89 on Nov 20, up 0.38% on the day. The next earnings report for KNSA is expected around Mon, Jan 11, 2027, after the close. For the quarter ended Sep 2026, KNSA reported EPS of $0.56 on revenue of $286.0M, with revenue up 58.1% from a year ago. Over its last 8 reports the stock moved an average of 15.1% the session after earnings. Over the last 12 months KNSA insiders bought $0 of stock on the open market and sold $121.7M, according to SEC Form 4 filings.

AI Auto Pilots
Is KNSA in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold KNSA.

Key Stats

Last 12 months
Results
Revenue
$946.0M
+58.2% vs a year ago
Net income
$109.6M
+205.1% vs a year ago
EPS (diluted)
$1.32
+193.3% vs a year ago
Free cash flow
$197.2M
20.8% margin
Balance sheet
Cash & equivalents
$81.7M
At Sep 30
Shareholder equity
$710.2M
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $38.5M$38.5MFY2021FY2022: $220.2M$220.2MFY2022FY2023: $270.3M$270.3MFY2023FY2024: $423.2M$423.2MFY2024FY2025: $677.6M$677.6MFY2025

From KNSA's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Oct 27). Last 12 months adds up the four latest quarters.

Next report
Jan 11
Estimated date · After the close
Reported EPS
$0.56
Quarter ended Sep 2026
Year ago EPS
$0.23
+143.5% on a GAAP basis
Revenue
$286.0M
+58.1% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.12Dec '24Mar 2025: $0.11Mar '25Jun 2025: $0.23Jun '25Sep 2025: $0.23Sep '25Dec 2025: $0.18Dec '25Mar 2026: $0.27Mar '26Jun 2026: $0.30Jun '26Sep 2026: $0.56Sep '26Latest $0.56
Revenue by quarter
Dec 2024: $122.5MDec '24Mar 2025: $137.8MMar '25Jun 2025: $156.8MJun '25Sep 2025: $180.9MSep '25Dec 2025: $202.1MDec '25Mar 2026: $214.3MMar '26Jun 2026: $243.6MJun '26Sep 2026: $286.0MSep '26Latest $286.0M
How KNSA moved after its last 8 reports
Average move the session after a report ±15.1%
Oct 27, 2026Time not announced+22.2%
Jul 28, 2026Time not announced+25.0%
Apr 28, 2026Time not announced+23.5%
Feb 24, 2026Time not announced−8.2%
Jan 12, 2026After the close−6.1%
Oct 28, 2025Time not announced−2.9%
Jul 29, 2025Time not announced+12.3%
Apr 29, 2025Time not announced+20.5%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on KNSAStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on KNSA
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on KNSA

Technical Analysis

KNSA · as of the Nov 20 close · updated each morning
Uptrend

The stock is 1% above its 20 day and 11% above its 50 day average. It is 32% above its 200 day average, so the longer trend is still up. Momentum is neutral (RSI 56). The nearest support is the 20 day average at $93.18, and the nearest resistance the Pivot at $93.95.

Short trendBullish
Long trendBullish
MomentumNeutral
StretchNormal
VolatilityNormal, 4.3%/day
Key levels
$99.3152 week high+5.8%
$97.96Swing high (Nov 16)+4.3%
$95.23Pivot R1+1.4%
$93.95Pivot+0.1%
$93.89Last close
$93.1820 day average−0.8%
$92.62Pivot S1−1.4%
$87.30Swing low (Nov 5)−7.0%
$83.8950 day average−10.7%
$78.48100 day average−16.4%
$64.09200 day average−31.7%
$37.0252 week low−60.6%
Indicators
RSI (14)55.81Middle of its rangeNeutral
MACD3.25Below its signal lineBearish
Stochastic57.1Middle of its rangeNeutral
ADX (14)20.6Weak trend
Williams %R-45.1Oversold below −80, overbought above −20Neutral
CCI (20)20.6Oversold below −100, overbought above 100Neutral
Rate of change+0.0%Change over 10 sessionsBullish
ATR (14)$4.05Typical daily range, 4.3% of price
MA 10Below
MA 20Above
MA 50Above
MA 100Above
MA 200Above
What happened before, for KNSA

What happened before

See how KNSA did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow KNSA usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How KNSA has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2018.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for KNSAHow many large options trades hit KNSA, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

KNSA Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲183 buying vs 108 selling
  • ▲Shares held by funds +1.0%
  • ▲Funds holding +38
  • ▲Superinvestors: 3 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holding
Q3 2026This quarterLast quarterChange
Funds holding304266+14.3%
In funds' top 1065+20.0%
Held by funds–––
New / increased64 / 11968 / 86+18.8%
Reduced / sold out83 / 2581 / 26+0.9%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See KNSA institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

KNSA Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$121.7M28 sales · 8 insiders
100% of the selling was under pre-arranged trading plans.
2025-12 sold $3.1M2026-01 sold $503K2026-02 sold $1.6M2026-03 sold $3.5M2026-04 sold $28.3M2026-05 sold $5.8M2026-07 sold $299K2026-09 sold $369K2026-10 sold $3.4M2026-11 sold $74.8MDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Nov 9Michael R MegnaChief Accounting OfficerSale plan11,280$98.54$1.1M
Nov 4Sanj K PatelChairman & CEOSale plan151,300$94.71$14.3M
Nov 3Sanj K PatelChairman & CEOSale plan402,494$92.92$37.4M
Nov 2John F. PaoliniChief Medical OfficerSale plan96,000$93.09$8.9M
Nov 2Mark RagosaCFOSale plan36,783$92.16$3.4M
Nov 2Ross MoatCOOSale plan103,585$92.93$9.6M
Every insider buy and sale for KNSA over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See KNSA insider trades →

From SEC Form 4 filings by KNSA's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether KNSA is in one of them and how their past KNSA trades turned out.

KNSA in the AI portfolios
Loading…

KNSA News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered KNSA in an article yet. Here's the latest on the wider market.

KNSA in the news

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals is a drug developer based in London that focuses on cardiovascular diseases. Its main product, ARCALYST, is approved in the United States for recurrent pericarditis, an inflammatory condition of the heart lining, and for certain autoinflammatory syndromes. The company sells ARCALYST in the United States through specialty pharmacies, has licensed partners in other regions, and is developing KPL-387, an investigational antibody that targets the same inflammation pathway. Its customers are patients and the doctors who treat them.

Headquarters
London